220 related articles for article (PubMed ID: 22504168)
1. Incidence, outcome and predictors of bleomycin pulmonary toxicity in a university hospital in Oman.
Ahmed BM; Al-Zakwani IS
J Oncol Pharm Pract; 2013 Mar; 19(1):3-7. PubMed ID: 22504168
[TBL] [Abstract][Full Text] [Related]
2. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.
Martin WG; Ristow KM; Habermann TM; Colgan JP; Witzig TE; Ansell SM
J Clin Oncol; 2005 Oct; 23(30):7614-20. PubMed ID: 16186594
[TBL] [Abstract][Full Text] [Related]
3. Late pulmonary complications of treating Hodgkin lymphoma: bleomycin-induced toxicity.
Jóna Á; Miltényi Z; Ujj Z; Garai I; Szilasi M; Illés Á
Expert Opin Drug Saf; 2014 Oct; 13(10):1291-7. PubMed ID: 25135756
[TBL] [Abstract][Full Text] [Related]
4. Risk of pulmonary toxicity of bleomycin and filgrastim.
Laprise-Lachance M; Lemieux P; Grégoire JP
J Oncol Pharm Pract; 2019 Oct; 25(7):1638-1644. PubMed ID: 30319063
[TBL] [Abstract][Full Text] [Related]
5. Uncommon manifestation of bleomycin-induced pulmonary toxicity in a patient with Hodgkin's disease.
Garipidou V; Vakalopoulou S; Zafiriadou E; Kaloutsi V; Tziomalos K; Perifanis V
Ann Oncol; 2005 Mar; 16(3):514-5. PubMed ID: 15668264
[No Abstract] [Full Text] [Related]
6. Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma.
Ngeow J; Tan IB; Kanesvaran R; Tan HC; Tao M; Quek R; Lim ST
Ann Hematol; 2011 Jan; 90(1):67-72. PubMed ID: 20676640
[TBL] [Abstract][Full Text] [Related]
7. Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma.
Sun HL; Atenafu EG; Tsang R; Kukreti V; Marras TK; Crump M; Kuruvilla J
Leuk Lymphoma; 2017 Nov; 58(11):2607-2614. PubMed ID: 28504035
[TBL] [Abstract][Full Text] [Related]
8. Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis.
Azoulay E; Herigault S; Levame M; Brochard L; Schlemmer B; Harf A; Delclaux C
Crit Care Med; 2003 May; 31(5):1442-8. PubMed ID: 12771616
[TBL] [Abstract][Full Text] [Related]
9. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
[TBL] [Abstract][Full Text] [Related]
10. Life threatening lung toxicity induced by low doses of bleomycin in a patient with Hodgkin's disease.
Real E; Roca MJ; Viñuales A; Pastor E; Grau E
Haematologica; 1999 Jul; 84(7):667-8. PubMed ID: 10406918
[No Abstract] [Full Text] [Related]
11. Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity.
Kawai K; Hinotsu S; Tomobe M; Akaza H
Jpn J Clin Oncol; 1998 Sep; 28(9):546-50. PubMed ID: 9793027
[TBL] [Abstract][Full Text] [Related]
12. Late pulmonary toxicity of bleomycin.
Willenbacher W; Mumm A; Bartsch HH
J Clin Oncol; 1998 Sep; 16(9):3205. PubMed ID: 9738596
[No Abstract] [Full Text] [Related]
13. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
Brusamolino E; Baio A; Orlandi E; Arcaini L; Passamonti F; Griva V; Casagrande W; Pascutto C; Franchini P; Lazzarino M
Clin Cancer Res; 2006 Nov; 12(21):6487-93. PubMed ID: 17085663
[TBL] [Abstract][Full Text] [Related]
14. Low incidence of long-term respiratory impairment in Hodgkin lymphoma survivors.
Avivi I; Hardak E; Shaham B; Igla M; Rowe JM; Dann EJ
Ann Hematol; 2012 Feb; 91(2):215-21. PubMed ID: 21603918
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary function abnormalities in childhood cancer survivors treated with bleomycin.
De A; Guryev I; LaRiviere A; Kato R; Wee CP; Mascarenhas L; Keens TG; Venkatramani R
Pediatr Blood Cancer; 2014 Sep; 61(9):1679-84. PubMed ID: 24789770
[TBL] [Abstract][Full Text] [Related]
16. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
Villani F; Busia A; Villani M; Laffranchi A; Viviani S; Bonfante V
Anticancer Res; 2009 Feb; 29(2):777-83. PubMed ID: 19331235
[TBL] [Abstract][Full Text] [Related]
17. Bleomycin-associated Lung Toxicity in Childhood Cancer Survivors.
Zorzi AP; Yang CL; Dell S; Nathan PC
J Pediatr Hematol Oncol; 2015 Nov; 37(8):e447-52. PubMed ID: 26422284
[TBL] [Abstract][Full Text] [Related]
18. Bleomycin induced pulmonary toxicity in patients with germ cell tumours.
Usman M; Faruqui ZS; ud Din N; Zahid KF
J Ayub Med Coll Abbottabad; 2010; 22(3):35-7. PubMed ID: 22338413
[TBL] [Abstract][Full Text] [Related]
19. Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia.
Ho P; Sherman P; Grigg A
Eur J Haematol; 2012 May; 88(5):416-21. PubMed ID: 22296221
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity.
Friedberg JW; Neuberg D; Kim H; Miyata S; McCauley M; Fisher DC; Takvorian T; Canellos GP
Cancer; 2003 Sep; 98(5):978-82. PubMed ID: 12942565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
